
FDA Approves Venglustat as First Therapy for Neurological Manifestations of Type 3 Gaucher Disease
Key Takeaways
- Venglustat, a glucosylceramide synthase inhibitor that crosses the blood–brain barrier, targets CNS glycosphingolipid pathobiology unmet by ERT or prior substrate reduction approaches in GD3.
- LEAP2MONO randomized 43 ERT-stabilized GD3 patients ≥12 years to double-blind, double-dummy venglustat vs imiglucerase, using a composite neurological primary endpoint at 52 weeks.
The FDA approved oral venglustat for neurological manifestations of type 3 Gaucher disease after the phase 3 LEAP2MONO trial showed superiority over imiglucerase on a combined ataxia and cognition measure.
The FDA has approved venglustat (Infilbray; Sanofi), an oral, brain-penetrant glucosylceramide synthase inhibitor (GCSi), for the treatment of neurological manifestations of type 3 Gaucher disease (GD3) in adult and pediatric patients weighing at least 15 kg. The decision makes venglustat the first therapy approved to address the neurological symptoms of the chronic neuronopathic form of the disease.1,2
Approval was based on the phase 3 LEAP2MONO trial (NCT05222906), in which once-daily venglustat demonstrated superiority over intravenous enzyme replacement therapy (ERT) on a combined measure of ataxia and cognition at 52 weeks. Pramod Mistry, MBBS, PhD, MA, MD, director of the
LEAP2MONO Trial Design and Results
LEAP2MONO was a double-blind, double-dummy, active-comparator study that randomly assigned 43 patients 12 years and older with GD3 1:1 to venglustat plus placebo infusion or imiglucerase every 2 weeks plus placebo tablet.2 Participants had received ERT for at least 3 years and had reached therapeutic goals for systemic disease.1,2
The primary end point was a prespecified global test combining change from baseline to week 52 in the 4-item modified Scale for the Assessment and Rating of Ataxia (SARA) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total scale index score. Venglustat showed statistically significant superiority over imiglucerase (P = .0137).2 Systemic end points (spleen and liver volume, hemoglobin, platelet count) and cerebrospinal fluid and plasma glucosylceramide and glucosylsphingosine levels were also assessed, but neither the company nor the FDA reported numerical results for the individual components or secondary end points. An open-label extension is ongoing.2
Safety
The label includes warnings and precautions for suicidal ideation and behavior, lens opacification in pediatric patients, and embryo-fetal toxicity; the FDA noted the latter 2 risks were identified in animal studies.1,2 During the 52-week primary analysis, adverse reactions more common with venglustat (n = 21) than imiglucerase (n = 22) included diarrhea (14% vs 0%), splenomegaly (14% vs 0%), nausea (14% vs 5%), depression (10% vs 0%), gastroenteritis (10% vs 0%), and vomiting (10% vs 5%).2
Clinical Context
Gaucher disease is an inherited lysosomal storage disorder caused by deficient glucocerebrosidase activity, leading to glycosphingolipid accumulation in the spleen, liver, bone marrow, and, in neuronopathic forms, the central nervous system.2 In GD3, patients develop hepatosplenomegaly, anemia, thrombocytopenia, and bone disease alongside progressive neurological involvement that can affect balance, coordination, speech, memory, and cognition.1,2 ERT and substrate reduction therapy improve systemic disease, but before this approval no therapy had been approved for its neurological manifestations.3
Mechanism and Development History
Venglustat inhibits glucosylceramide synthase, reducing synthesis of the glycosphingolipids that accumulate in GD3, and it crosses the blood-brain barrier.1,2 In the open-label phase 2 LEAP trial (NCT02843035), 11 adults with GD3 received venglustat 15 mg daily in combination with maintenance imiglucerase for 1 year, with primary end points of safety, tolerability, and change in glycosphingolipid concentrations.3 Separately, the phase 2 MOVES-PD trial in GBA1-associated Parkinson disease did not show benefit over placebo.4
REFERENCES
1. FDA. FDA approves first drug to treat neurological symptoms of type 3 Gaucher disease. News release. November 18, 2026. Accessed November 19, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease
2. Sanofi’s infilbray approved in the US as the first medicine to treat neurological manifestations of type 3 Gaucher disease. News release. Sanofi. November 18, 2026. Accessed November 19, 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-11-18-22-19-06-3406209
3. Schiffmann R, Cox TM, Dedieu JF, et al. Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial. Brain. 2023;146(2):461-474. doi:10.1093/brain/awac379
4. Giladi N, Alcalay RN, Cutter G, et al. Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2023;22(8):661-671. doi:10.1016/S1474-4422(23)00205-3
Related to this article








